Mylan Suffers Biggest Drop in Almost Two Decades Amid Drug Pain

(Bloomberg) -- Mylan NV fell the most in 19 years after the drugmaker offered no updates on a strategic review that has been going on for 10 months as its businesses struggle around the globe.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.